Every 8-K that Monogram Technologies Inc. (MGRM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MGRM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MGRM filings page.
Monogram Technologies completed its previously announced merger with Zimmer Biomet through Honey Badger Merger Sub, with Monogram surviving as a wholly owned subsidiary of Zimmer Biomet. The Merger was effected under an Agreement and Plan of Merger dated July 11, 2025, as amended on August 27, 2025. Holders of in‑the‑money stock options immediately prior to the Effective Time had those options cancelled and converted into cash equal to the excess of the Cash Amount over the option exercise price plus one contingent value right (CVR) per share for vested portions, subject to withholding; certain options with exercise prices between the Cash Amount and $16.41 were converted solely into a CVR with the CVR payment reduced by the amount the exercise price exceeded the Cash Amount. The Hart‑Scott‑Rodino waiting period was extended and subsequently expired at 11:59 p.m. ET on October 6, 2025. Amended charter and bylaws dated October 7, 2025 and a press release dated October 7, 2025 are filed as exhibits.
Monogram Technologies Inc. filed an update on its planned merger with Zimmer Biomet Holdings. Zimmer Biomet, as the acquiring party, voluntarily withdrew and, on the same day, resubmitted its pre-merger Notification and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act in consultation with Monogram. This refiling starts a new 30-day antitrust waiting period that runs until October 6, 2025, at 11:59 p.m. Eastern Time, unless it is terminated earlier or extended.
The companies describe this withdraw-and-refile step as a standard procedure to give the Federal Trade Commission more time to review the transaction. Monogram and Zimmer Biomet state they are working constructively with FTC staff and continue to expect the merger to close in the second half of 2025, subject to required regulatory approvals, approval of the merger agreement by Monogram shareholders, and other customary closing conditions.
Monogram Technologies Inc. furnished an update on its communications with shareholders about a pending transaction. On August 29, 2025, the company began sending texts and emails to stockholders to remind them of the 2025 special meeting of stockholders to approve the previously announced acquisition by Zimmer Biomet Holdings, Inc. These messages are meant to alert investors to the upcoming vote. The full text of the communications is included as Exhibits 99.1 through 99.4 to this report.
Monogram Technologies Inc. (MGRM) filed an 8-K on 30 Jul 2025 under Item 7.01 to furnish an email sent to shareholders.
The email directs investors to the FAQ section on the company’s Investor Relations website that addresses the previously announced Zimmer Biomet Holdings, Inc. acquisition (14 Jul 2025). No new financial statements, valuation metrics, or amended deal terms are included. The communication is provided as Exhibit 99.1 and, consistent with Reg FD, is treated as “furnished,” not “filed,” limiting Exchange Act liability.
Item 9.01 lists (i) Exhibit 99.1—Shareholder Email and (ii) the Inline XBRL cover file. No other reportable events were disclosed.
Monogram Technologies Inc. (Nasdaq: MGRM) filed a Form 8-K (Item 7.01 Regulation FD) to furnish a press release dated 29 July 2025 announcing completion of the world’s first fully autonomous, saw-based robotic total knee replacement. The surgery used Monogram’s proprietary mBōs™ TKA System and was performed at Krishna Shalby Hospital in Ahmedabad, India.
The company positions the procedure as proof-of-concept for closed-loop robotic orthopedic surgery, potentially accelerating its commercialization roadmap and strategic partnerships. No financial results, guidance, or transactions were disclosed; the press release is provided as Exhibit 99.1 and is deemed “furnished,” not “filed,” limiting liability under the Exchange Act.
Forward-looking-statement language flags risks around capital needs, regulatory approvals, partner dependence and litigation. Other 8-K items (7.01, 9.01) contain only exhibit references; no pro-forma financials or statements accompany the filing.
Monogram Technologies Inc. (Nasdaq: MGRM) filed an 8-K on 28-Jul-2025 under Item 7.01 to furnish shareholder FAQs related to its previously announced acquisition by Zimmer Biomet Holdings, Inc. (announced 14-Jul-2025). The filing labels the material as soliciting under Rule 14a-12, signalling its use in the forthcoming proxy process. Exhibit 99.1 contains the full FAQ document and is incorporated by reference.
The information is being “furnished” rather than “filed,” so it is not subject to Section 18 liability and will not be automatically incorporated into other SEC filings. No additional financial terms, valuation, or closing timeline are provided. The company reiterates its emerging-growth company status and maintains Nasdaq listing under the ticker MGRM.